Oral Sessions
(Day1, Day2, Day3, Day4)
Poster Presentations
(Day1, Day2, Day3, Day4)
Luncheon Seminars
(Day1, Day2, Day3, Day4)
Oral Sessions
- Day 3, May 17(Thu.) 16:35-16:55 Room A (OrBit Hall)
-
3A-O2-P-1635 PDF
Discovery of colorectal cancer biomarkers in serum extracellular vesicles by targeted proteomics
Many biomarker candidate proteins for colorectal cancer (CRC) have been reported in the earlier literature including our report, however, none of them has been applied for clinical test or validated as useful biomarker. Recent advances in targeted proteomics enabled to validate hundreds of biomarker candidates. In this study, we aimed to verify previously reported CRC biomarker candidate proteins in serum extracellular vesicles (EVs) of CRC patients by selected reaction monitoring.
Using this technology, we verified 725 previously reported CRC biomarker candidate proteins that are functionally correlated with CRC in EVs from patients. Of these, 356 proteins were quantified, and 34 peptides (22 proteins) showed significant differences in the serum EVs between healthy controls and CRC patients of two independent cohorts (n = 77 and 84).
These peptides were evaluated as single or multiple markers. Four single peptides in annexin family proteins and eight combinations of peptides showed area under the curve >0.9 for discriminating between healthy controls and CRC patients. Furthermore, sensitivities of the four peptides of annexins A3, A4, and A11 for detection of stage 1 and stage 2 early CRC were >80%, which greatly exceeds the sensitivity of CEA. These peptides are promising biomarkers for early detection of CRC